Sentence examples for discontinuation across from inspiring English sources

Patient discontinuation across the 56-week study was 25.4% and 29.3% for the onabotulinumtoxinA and placebo study arms, respectively, with no major differences in the reasons for withdrawal from the study (Fig. 1).

The most common reasons for treatment discontinuation across treatment arms were loss to follow-up and adverse events (Fig.  1).

The most common reasons for discontinuation across all depression-related categories were adverse events and withdrawn consent with asenapine, lack of efficacy and withdrawn consent with placebo, and lack of efficacy with olanzapine (Table 1).

The Kaplan Meier estimator was also used to depict the probability of treatment discontinuation across strata of significant predictors, and group comparisons were made using the log-rank test.

We varied the definition of discontinuation across a range of possible options and examined factors associated with discontinuation, which is expected to be useful for future analyses that examine new reasons for patients to stop therapy such as a drug holidays [ 15, 16].

For each medication, the sum of the discontinuation rates across the 4 reasons equals the annual all-cause discontinuation rate.

This same subgroup also recorded the greatest differential in switch therapy discontinuation rates across all three subgroups (Fig. 5).

Discontinuation rates across the groups at 26 and 52 weeks were comparable to the rates observed in similar diabetes trials previously reported in the medical literature (23– 23).

Differences in overall discontinuation rate across studies appeared to be driven primarily by higher rates of discontinuation due to lack of efficacy in the oral olanzapine studies 1 and 3 relative to the olanzapine LAI study.

Eleven (12.1%) subjects discontinued before week 26; rates of discontinuation were similar across both canagliflozin groups.

Summaries of the treatment discontinuations observed across the included RCTs are shown in Table  4.